On May 10, Shuaizhijia Group formally signed a strategic memorandum of understanding with Denmark-based NordicVita Pharmaceuticals. The two parties will collaborate on two innovative prescription drugs in the cardiovascular-metabolic space, spanning product evaluation, China registration path planning and commercialization execution.
NordicVita holds multiple patents in cardiovascular metabolism and has extensive European market validation data. Shuaizhijia Group will leverage its local capabilities in regulatory affairs, distribution networks and academic promotion to drive efficient market entry in China.
CEO James Wang commented: "This partnership marks an important step in our internationalization strategy. Cardiovascular was chosen based on both China's clinical demand and shared values around compliance and quality management."
Future updates will continue to focus on compliance, quality and cross-border coordination as key milestones progress.